
    
      This trial will be a single-blind, placebo-controlled, dose escalating between cohorts,
      single and multi-dose, multi-center study to evaluate the safety, tolerability and
      pharmacokinetic profile of levofloxacin administered as MP-376 once, then twice daily for 14
      days by the aerosol route to CF patients.
    
  